Thus, CDK5 contributes to the pathobiology of CKD, and targeting the CG1/CDK5 pathway via inhibition of CDK5 is a potential therapeutic approach to prevent AKI-to-CKD transition. This evidence concerns the gene CDK5 and acute kidney injury.